Efficacy and safety of intravitreal dexamethasone implant for recurrent pseudophakic cystoid macular edema

Session Details

Session Title: Presented Poster Session: Cataract Surgery Complications and Management

Session Date/Time: Saturday 05/09/2015 | 09:30-10:50

Paper Time: 09:30

Venue: Poster Village: Pod 1

First Author: : S.Vasavada INDIA

Co Author(s): :    A. Vasavada   A. Sudhalkar   V. Vasavada        

Abstract Details

Purpose:

To provide preliminary data of the efficacy and safety of an intravitreal dexamethasone implant in recurrent/recalcitrant pseudophakic Cystoid Macular Edema(CME)

Setting:

Iladevi Cataract & IOL Research Centre, & Raghudeep Eye Hospital, Ahmedabad, India

Methods:

Prospective observational study included 25 patients with Cystoid Macular Edema following uneventful phacoemulsification with in-the-bag IOL implantation,not responding to conventional treatment.Patients with pre-existing diabetic retinopathy, uveitis or uncontrolled diabetes excluded.Diagnosis of Pseudophakic CME was confirmed by OCT and Fluorescein angiography.All patients received a trial of topical NSAIDS and steroids for at least 2 months. In recurrent/non-responding cases, Intravitreal Dexamethasone implant(Inj. Ozurdex, Allergan) was given using a standardized technique.Visual acuity and OCT scans measured on a monthly basis pre- and post-intravitreal injections.Minimum follow-up was 6 months. Outcome measures were change in visual acuity and central macular thickness on OCT

Results:

Ongoing study. Early results(14 eyes).Median age 66.24±7.42 years,Median follow-up 10.4±2.5 months.7 eyes had recurrent edema and 7 had recalcitrant edema.3 eyes with recalcitrant edema had received posterior subtenon triamcinolone injection in addition to standard topical treatment.Mean baseline VA was 0.52±0.21 logMAR and improved to 0.12±0.07 logMAR at final follow-up (p<0.001).71% had 20/20,93% had 20/40 or better vision at final follow-up.OCT central macular thickness ; 408.24±31.2 microns at baseline and 210.2±21.24 microns at final follow up(p=0.012).No eye had rise in IOP.One eye had recurrent edema two months after injection.No other adverse events noted. Results will be updated at time of presentation

Conclusions:

Preliminary data shows that Intravitreal dexamethasone implant appears to be effective, long lasting and reasonably safe in the treatment of recurrent/recalcitrant CME post cataract surgery and can possibly reduce visual disability secondary to CME.

Financial Interest:

NONE